Stark R, Feehan J, Mousa A, Andrews ZB, de Courten B
it also has a significant impact on your digestive system
The trial was registered at ClinicalTrials.gov (registration: NCT05073835), the UK Medicines and Healthcare products Regulatory Agency and the European Union Drug Regulating Authority Clinical Trials (EudraCT no
NICEs independent appraisal committee has recommended that semaglutide can be offered as an option for weight management, alongside a reduced-calorie diet and increased physical activity in adults, only if: they have at least one weight-related comorbidity and: a BMI at least 35.0 kg/m2, or exceptionally, a BMI of 30.0 kg/m2 to 34.9 kg/m2 if they are referred to tier 3 services based on the criteria in NICEs clinical guideline on obesity: identification, assessment and management
Currently, subcutaneous delivery via needle-based syringes or pens is the common route of administration for GLP-1 receptor agonists
Drinking plenty of water, eating smaller meals, and avoiding heavy or greasy foods can help reduce digestive discomfort during the initial phase of treatment
)
